LSBio logo with text
Products
Research Areas
COVID-19
Resources
Contact Us
Login
Quick Order
Cart Cart lightblue
Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order
Cart
How To Buy
Contact Us

Locations

Orders Processing,
Shipping & Receiving,
Warehouse

2 Shaker Rd Suites
B001/B101
Shirley, MA 01464

Production Lab

Floor 6, Suite 620
20700 44th Avenue W
Lynnwood, WA 98036

Telephone Numbers


Tel: +1 (206) 374-1102
Fax: +1 (206) 577-4565

Contact Us


Additional Contact Details

Distributors
Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order
Proteins > VEGFA / VEGF > LS-G136183
 
Print Page  
Catalog Number Size Price
LS-G136183-0.2 0.2 mg (0.5 mg/ml) $884 
VEGFA / VEGF Protein - Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of ranibizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29928 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
VEGFA / VEGF Protein - Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of bevacizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29865 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
VEGFA / VEGF Protein - Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of ranibizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29928 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
VEGFA / VEGF Protein - Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of bevacizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29865 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
1 of 2
2 of 2

Human VEGFA / VEGF Protein (Recombinant) (aa27-141) - LS-G136183

Human VEGFA / VEGF Protein (Recombinant) (aa27-141) - LS-G136183

Submit Review LSBio Guarantee
Description:
VEGFA / VEGF Protein LS-G136183 is a Recombinant Human VEGFA / VEGF produced in E. coli aa 27-141. For Research Use Only
Price
Catalog Number
$884
LS-G136183-0.2
Toll Free North America
206-374-1102
For Research Use Only
Specifications Publications Reviews Images Popular VEGFA / VEGF Proteins Request SDS/MSDS

Overview

Description:
VEGFA / VEGF Protein LS-G136183 is a Recombinant Human VEGFA / VEGF produced in E. coli aa 27-141. For Research Use Only

Specifications

Type
Recombinant Protein
Target
VEGFA / VEGF
Synonyms
VEGFA | VPF | Vascular permeability factor | VEGF | VEGF-A | MVCD1
Species
Human
Modifications
Unmodified
Conjugations
Unconjugated
Region
aa 27-141
Predicted Molecular Weight
~14 kDa
Expression System
E. coli
Source Species
E. coli
Purification
Purified by affinity chromatography. Greater than 90% by reducing SDS-PAGE and Coomassie blue staining
Usage Summary
Recommended applications: ELISA
Bio-Activity
Not Tested
Endotoxin
Not Tested
Presentation
20 mM Phosphate Buffer, 0.1 M NaCl, 1% Trehalose
Reconstitution
Centrifuge prior to reconstitution. The protein may appear as a film at the bottom of the vial. Reconstitute with ddH2O to a concentration of 0.5 mg/ml. Mix gently after reconstitution. Do not vortex.
Storage
Before reconstitution store at -70°C. Following reconstitution store at -20°C. Store undiluted. Do not use frost-free freezers. Avoid freeze-thaw cycles.
Restrictions
For research use only. Intended for use by laboratory professionals.
Guarantee
This protein carries the LSBio 100% Guarantee.
LSBio Guarantee
About VEGFA / VEGF
P15692 NM_003376 NP_003367.4

Publications (0)

Submit a Publication for LS-G136183

Customer Reviews (0)

Submit a review for LS-G136183

Images

Enzyme-Linked Immunosorbent Assay

VEGFA / VEGF Protein - Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of ranibizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29928 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of ranibizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29928 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.

Enzyme-Linked Immunosorbent Assay

VEGFA / VEGF Protein - Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of bevacizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29865 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of bevacizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29865 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.

Enzyme-Linked Immunosorbent Assay

VEGFA / VEGF Protein - Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of ranibizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29928 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of ranibizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29928 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.

Enzyme-Linked Immunosorbent Assay

VEGFA / VEGF Protein - Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of bevacizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29865 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of bevacizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29865 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.

Enzyme-Linked Immunosorbent Assay

VEGFA / VEGF Protein - Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of ranibizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29928 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of ranibizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29928 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.

Enzyme-Linked Immunosorbent Assay

VEGFA / VEGF Protein - Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of bevacizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29865 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of bevacizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29865 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.

Enzyme-Linked Immunosorbent Assay

VEGFA / VEGF Protein - Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of ranibizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29928 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of ranibizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29928 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.

Enzyme-Linked Immunosorbent Assay

VEGFA / VEGF Protein - Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of bevacizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29865 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of bevacizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29865 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.

Popular VEGFA / VEGF Proteins

VEGFA / VEGF Protein
Human VEGFA / VEGF Protein (Recombinant) - LS-G1691
Source: E. coli
Tag: None
VEGFA / VEGF Protein - Recombinant Vascular Endothelial Growth Factor A By SDS-PAGE
Rat VEGFA / VEGF Protein (Recombinant His) (aa27-190) - LS-G11695
Source: E. coli
Tag: His
VEGFA / VEGF Protein - Recombinant Vascular Endothelial Growth Factor A (VEGFA) by SDS-PAGE
Rhesus monkey VEGFA / VEGF Protein (Recombinant His, N-Terminal) (Pro20-Arg224) - LS-G132674
Source: E. coli
Tag: His, N-Terminal
VEGFA / VEGF Protein - Recombinant Vascular Endothelial Growth Factor A By SDS-PAGE
Rabbit VEGFA / VEGF Protein (Recombinant His-T7) (aa1-120) - LS-G11693
Source: E. coli
Tag: His-T7
VEGFA / VEGF Protein
Human VEGFA / VEGF Protein (Recombinant) - LS-G515
Source: E. coli
Tag: None
Product
Mouse VEGFA / VEGF Protein (Recombinant) - LS-G131556
Source: Escherichia coli
Tag: None

Request SDS/MSDS

To request an SDS/MSDS form for this product, please contact our Technical Support department at:

Technical.Support@LSBio.com
Requested From: United States
Date Requested: 7/3/2024
Family of Companies
Site Links Home All Antibodies How To Buy All Proteins Distributors All ELISA & Assay Kits Reviews PathPlus™ Antibodies
Follow LSBio View Cart Register or Login
Copyright © 2022 LifeSpan BioSciences, Inc - Privacy Policy
Contact Us

2 Shaker Rd Suites
B001/B101
Shirley, MA 01464

Tel: +1 (206) 374-1102
Fax: +1 (206) 577-4565

To place an order:
Orders@LSBio.com

For questions about orders:
Customer.Support@LSBio.com

For technical assistance:
Technical.Support@LSBio.com